NASDAQ: BPMC

Blueprint Medicines Corporation

Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. The company’s approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. The company believes their ability to identify novel drivers of disease, coupled with their proprietary library of novel and diverse chemical compounds, uniquely enables them to craft kinase therapies against new and difficult-to-drug targets.